Cargando…
Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation
Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of...
Autores principales: | Fujiki, Tamami, Ando, Fumiaki, Murakami, Kana, Isobe, Kiyoshi, Mori, Takayasu, Susa, Koichiro, Nomura, Naohiro, Sohara, Eisei, Rai, Tatemitsu, Uchida, Shinichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592894/ https://www.ncbi.nlm.nih.gov/pubmed/31239473 http://dx.doi.org/10.1038/s41598-019-45539-8 |
Ejemplares similares
-
Sodium–calcium exchanger 1 is the key molecule for urinary potassium excretion against acute hyperkalemia
por: Shoda, Wakana, et al.
Publicado: (2020) -
ZNF185 prevents stress fiber formation through the inhibition of RhoA in endothelial cells
por: Suzuki, Soichiro, et al.
Publicado: (2023) -
Association of Admission Functional Status and Body Mass Index with Mortality in Patients Receiving Chronic Dialysis: A Nationwide Observational Cohort Study
por: Mandai, Shintaro, et al.
Publicado: (2023) -
The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1
por: Zeniya, Moko, et al.
Publicado: (2017) -
Burden of kidney disease on the discrepancy between reasons for hospital admission and death: An observational cohort study
por: Mandai, Shintaro, et al.
Publicado: (2021)